Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05780047 · ClinicalTrials.gov registry record · NA

Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age

A NA study, sponsored by Million Marker Wellness.

Completed
Registry status
NA
Development phase
434
Enrollment target

NCT05780047: Completed NA study, sponsored by Million Marker Wellness.

NCT05780047 is a NA study that has completed, run by Million Marker Wellness. The registered enrollment target is 434 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05780047, a NA study, has completed, sponsored by Million Marker Wellness.

COMPLETED
Registry status
NA
Development phase
434 participants
Enrollment target

Study Summary

The goal of this intervention study is to determine to what extent the Million Marker (MM) program reduces users' endocrine disruption chemical (EDC) exposure levels and changes their environmental health awareness and behaviors. The main questions it aims to answer are: * Can the investigators see a reduction in EDC levels in participants' urine samples after using the MM Detect and Detox kit? * Can the investigators see a change in participants' environmental health literacy, knowledge, and behaviors after using MM's products and services? * How can Million Marker improve their app and platform to improve the user experience? Participants will collect their urine pre- and post-intervention, and will take a comprehensive exposure survey (via the MM app) before sending back their samples. This exposure survey will ask about participant's product use, diet, and lifestyle behaviors. Participants will also fill out surveys pre- and post-intervention assessing their perception of environmental health, as well as usability of the platform.

Primary Outcome

Urine samples collected pre- and post-intervention to measure changes in EDC levels

Interventions

  • DIAGNOSTIC_TEST Mail-in Urine Test for EDCs

Trial Details

FieldValue
Enrollment Target 434 participants
Start Date 2022-05-01
Est. Completion 2022-10-31
Phase NA
Million Marker Wellness

5 total trials

What the finished NCT05780047 record still lists

NCT05780047 is an interventional study that assigns participants to a tested intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower).

The record links to 0 conditions, and to 1 intervention - of which Mail-in Urine Test for EDCs is the first listed.

NCT05780047 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05780047 about?

NCT05780047 is a clinical study titled "Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age". The goal of this intervention study is to determine to what extent the Million Marker (MM) program reduces users' endocrine disruption chemical (EDC) exposure levels and changes their environmental health awareness and behaviors. The main questions it aims to answer are: * Can the investigators see...

What is the current status of trial NCT05780047?

This trial is currently completed. It is a NA study. The enrollment target is 434 participants. The study started on 2022-05-01. Estimated completion is 2022-10-31.

What interventions are being tested in trial NCT05780047?

The interventions under investigation include: Mail-in Urine Test for EDCs (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05780047?

This trial is sponsored by Million Marker Wellness, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05780047's enrollment target sits among peer trials

434 235th of 2000 higher than 1,766 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04743245 · 434 participants · NA

    Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

  • NCT06471920 · 434 participants · NA

    Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation

  • NCT07094113 · 434 participants · Phase 1

    AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  • NCT05563220 · 435 participants · Phase 1

    Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05780047, the US trial registry maintained by the National Library of Medicine. NCT05780047 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.